Sales for key drugs Prolia and XGEVA plummeted by 32% and 34% respectively in Q2 2026, a combined revenue drop of over $540 million versus prior year. This massive loss is due to patent expirations and new biosimilar competition, creating urgent pressure to optimize commercial operations and find cost efficiencies to protect margins.
Filing excerpt
The decreases in global Prolia sales for the three and six months ended June 30, 2026 were primarily driven by lower volume of 20% and 19%, respectively, and lower net selling price of 12% and 11%, respectively.
What this signalsFilings often name leadership changes, deals and spending plans.
Competitors
Regions named
sec-10qcompetitorNamedGet every 10-Q signal for Amgen and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Amgen this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/e8184aea-e6b9-4d07-b144-3266739f03a1 returns this record as JSON. POST /v1/companies/enrich returns every signal for amgen.com.
{
"signal_id": "e8184aea-e6b9-4d07-b144-3266739f03a1",
"signal_type": "sec-10q",
"signal_subtype": "competitorNamed",
"detected_at": "2026-08-11T08:12:05.369+00:00",
"company": {
"name": "Amgen",
"domain": "amgen.com"
},
"data": {
"detail": "Sales for key drugs Prolia and XGEVA plummeted by 32% and 34% respectively in Q2 2026, a combined revenue drop of over $540 million versus prior year. This massive loss is due to patent expirations and new biosimilar competition, creating urgent pressure to optimize commercial operations and find cost efficiencies to protect margins.",
"metrics": {
"pct": -0.33,
"timeframe": "current_quarter",
"pct_context": "Average YoY sales decline for Prolia (-32%) and XGEVA (-34%) in Q2",
"dollar_context": "Combined Q2 YoY revenue decline for Prolia ($363M) and XGEVA ($180M)",
"dollar_millions": 543
},
"summary": "Prolia & XGEVA sales fall over 30% due to biosimilar competition, losing over $540M in Q2",
"excerpts": "The decreases in global Prolia sales for the three and six months ended June 30, 2026 were primarily driven by lower volume of 20% and 19%, respectively, and lower net selling price of 12% and 11%, respectively.",
"relevance": 0.9,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/318154/000031815426000126/amgn-20260630.htm",
"filing_date": "2026-08-04",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "06/30",
"sales_relevance": "Competitive intelligence",
"signal_category": "market",
"regions_mentioned": [
"United States",
"ROW"
],
"competitors_mentioned": [
"biosimilars",
"generics"
]
}
}
curl https://signals.autobound.ai/v1/signals/e8184aea-e6b9-4d07-b144-3266739f03a1 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"amgen.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.